Marker Therapeutics (MRKR) Equity Ratio (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Equity Ratio data on file, last reported at 0.79 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.79, down 7.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.79 (down 7.21% YoY), and the FY2025 annual result was 0.88, up 4.52% from the prior year.
• Equity Ratio fell to 0.79 in Q1 2026 per MRKR's latest filing, from 0.88 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.88 in Q4 2025 and troughed at 0.54 in Q2 2022.
• A 5-year average of 0.75 and a median of 0.82 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio slumped 31.84% in 2022, then soared 61.85% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.57 in 2022, then soared by 44.09% to 0.82 in 2023, then climbed by 2.71% to 0.84 in 2024, then climbed by 4.52% to 0.88 in 2025, then fell by 10.15% to 0.79 in 2026.
• Business Quant data shows MRKR's Equity Ratio at 0.79 in Q1 2026, 0.88 in Q4 2025, and 0.85 in Q3 2025.